| H7T2 Stock | | | EUR 2.72 0.10 3.55% |
CEO
Christian Hogg is Chief Executive Officer, Executive Director of HUTCHMED LS 1 since 2018.
| Age | 53 |
| Tenure | 6 years |
| Phone | 852 2128 1188 |
| Web | http://www.hutch-med.com |
HUTCHMED Management Efficiency
The company has return on total asset
(ROA) of
(0.1932) % which means that it has lost $0.1932 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.2472) %, meaning that it generated substantial loss on money invested by shareholders. HUTCHMED's management efficiency ratios could be used to measure how well HUTCHMED manages its routine affairs as well as how well it operates its assets and liabilities.
HUTCHMED LS 1 has accumulated 36.69
M in total debt with debt to equity ratio
(D/E) of 0.04, which may suggest the company is not taking enough advantage from borrowing. HUTCHMED LS 1 has a current ratio of 4.32, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist HUTCHMED until it has trouble settling it off, either with new capital or with free cash flow. So, HUTCHMED's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like HUTCHMED LS 1 sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for HUTCHMED to invest in growth at high rates of return. When we think about HUTCHMED's use of debt, we should always consider it together with cash and equity.
HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. HUTCHMED Limited was incorporated in 2000 and is headquartered in Central, Hong Kong. HUTCHMED operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1280 people. HUTCHMED LS 1 (H7T2) is traded on Frankfurt Exchange in Germany and employs 2,110 people.
Management Performance
HUTCHMED LS 1 Leadership Team
Elected by the shareholders, the HUTCHMED's board of directors comprises two types of representatives: HUTCHMED inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HUTCHMED. The board's role is to monitor HUTCHMED's management team and ensure that shareholders' interests are well served. HUTCHMED's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HUTCHMED's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edith Shih, Company Secretary, Non-Executive Director | |
| Chig Cheng, Chief Financial Officer, Executive Director | |
| May Wang, Senior Vice President - business development & strategic alliances | |
| Mark Lee, Senior Vice President - Corporate Finance & Development | |
| Karen Ferrante, Independent Non-Executive Director | |
| Christian Hogg, Chief Executive Officer, Executive Director | |
| Weiguo Su, Chief Scientific Officer, Executive Director | |
| Shu Mok, Independent Non-Executive Director | |
| Graeme Jack, Independent Non-Executive Director | |
| Zhenping Wu, Senior Vice President - Pharmaceutical Sciences | |
| Dan Eldar, Non-Executive Director | |
| Simon To, Executive Chairman of the Board | |
| Paul Carter, Senior Independent Non-Executive Director | |
HUTCHMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HUTCHMED a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in HUTCHMED Stock
HUTCHMED financial ratios help investors to determine whether HUTCHMED Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HUTCHMED with respect to the benefits of owning HUTCHMED security.